Jacobs Levy Equity Management
UTHR icon

Jacobs Levy Equity Management’s United Therapeutics UTHR Stock Holding History

Jacobs Levy Equity Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Hold
2,268
– – 0.01% 661
2025
Q4 		$1.11M Hold
2,268
– – ﹤0.01% 665
2025
Q3 		$951K Sell
2,268
-5,666
-71% -$1.91M ﹤0.01% 731
2025
Q2 		$2.28M Hold
7,934
– – 0.01% 588
2025
Q1 		$2.45M Buy
7,934
+5,666
+250% +$1.94M 0.01% 614
2024
Q4 		$800K Hold
2,268
– – ﹤0.01% 749
2024
Q3 		$813K Hold
2,268
– – ﹤0.01% 763
2024
Q2 		$722K Hold
2,268
– – ﹤0.01% 794
2024
Q1 		$521K Sell
2,268
-72,203
-97% -$16.3M ﹤0.01% 814
2023
Q4 		$16.4M Sell
74,471
-118,205
-61% -$27.2M 0.08% 235
2023
Q3 		$43.5M Sell
192,676
-31,881
-14% -$7.34M 0.26% 90
2023
Q2 		$49.6M Sell
224,557
-32,733
-13% -$7.25M 0.29% 88
2023
Q1 		$57.6M Sell
257,290
-61,753
-19% -$15.2M 0.35% 70
2022
Q4 		$88.7M Sell
319,043
-46,576
-13% -$11.8M 0.6% 35
2022
Q3 		$76.6M Buy
365,619
+34,412
+10% +$7.69M 0.61% 29
2022
Q2 		$78M Sell
331,207
-14,369
-4% -$2.92M 0.6% 28
2022
Q1 		$62M Sell
345,576
-40,173
-10% -$7.65M 0.42% 54
2021
Q4 		$83.4M Sell
385,749
-102,263
-21% -$20.1M 0.56% 39
2021
Q3 		$90.1M Sell
488,012
-2,847
-0.6% -$561K 0.61% 32
2021
Q2 		$88.1M Sell
490,859
-14,036
-3% -$2.67M 0.6% 32
2021
Q1 		$84.5M Buy
504,895
+1,962
+0.4% +$327K 0.65% 27
2020
Q4 		$76.3M Sell
502,933
-25,633
-5% -$3.36M 0.67% 28
2020
Q3 		$53.4M Buy
528,566
+77,308
+17% +$8.48M 0.55% 38
2020
Q2 		$54.6M Buy
451,258
+86,678
+24% +$9.75M 0.59% 32
2020
Q1 		$34.6M Buy
364,580
+277,867
+320% +$26.4M 0.44% 54
2019
Q4 		$7.64M Buy
86,713
+78,253
+925% +$6.89M 0.07% 294
2019
Q3 		$675K Buy
+8,460
New +$681K 0.01% 673
2016
Q3 		– Sell
-24,278
Closed -$2.57M – 1135
2016
Q2 		$2.57M Buy
24,278
+14,878
+158% +$1.66M 0.05% 376
2016
Q1 		$1.05M Sell
9,400
-30,446
-76% -$3.85M 0.02% 556
2015
Q4 		$6.24M Buy
39,846
+21,319
+115% +$3.1M 0.12% 198
2015
Q3 		$2.43M Sell
18,527
-25,929
-58% -$4.16M 0.05% 324
2015
Q2 		$7.73M Sell
44,456
-69,017
-61% -$12.4M 0.15% 179
2015
Q1 		$19.6M Buy
113,473
+89,383
+371% +$13.6M 0.33% 103
2014
Q4 		$3.12M Sell
24,090
-4,035
-14% -$520K 0.05% 316
2014
Q3 		$3.62M Sell
28,125
-2,320
-8% -$239K 0.06% 285
2014
Q2 		$2.69M Buy
30,445
+4,660
+18% +$448K 0.04% 356
2014
Q1 		$2.42M Sell
25,785
-25,659
-50% -$2.62M 0.04% 371
2013
Q4 		$5.82M Sell
51,444
-21,070
-29% -$1.9M 0.09% 266
2013
Q3 		$5.72M Sell
72,514
-21,920
-23% -$1.6M 0.1% 254
2013
Q2 		$6.22M Buy
+94,434
New +$6.08M 0.11% 244

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jacobs Levy Equity Management's UTHR Position: Q1 2026 in Review

Jacobs Levy Equity Management held its United Therapeutics (UTHR) position steady in Q1 2026 at 2,268 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #661.

Jacobs Levy Equity Management first reported a position in UTHR in Q2 2013 and has held it in 40 quarters since. The position peaked at $90.1M in Q3 2021. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Jacobs Levy Equity Management held 2,268 shares of United Therapeutics worth $1.34M as of Q1 2026.
  • Jacobs Levy Equity Management left its United Therapeutics share count unchanged in Q1 2026.
  • United Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #661 holding.
  • Jacobs Levy Equity Management first reported a position in United Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Jacobs Levy Equity Management's United Therapeutics position peaked at $90.1M in Q3 2021.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.